Financials
Financial year 2025
IN2PHARMA from Kampenhout, company number BE0895730662, closed financial year 2025 with a result of € 909,969 after tax. For that financial year IN2PHARMA recorded a gross margin of € 2.4 million and equity of € 69,300. Compared with financial year 2024, the result moved from € 984,888 to € 909,969. The company is profitable. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 22, 2026.
€ 69,300
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 909,969
▼ 8% vs 2024
Profit after tax over the fiscal year.
€ 333,982
▲ 156% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 909,969 paid out
100 % of the profit went to the shareholders, mostly to PHC Group (100 % of the shares). That is where the money ends up.
People and assets in 2025
15.1
▲ 3.8 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 1.1 million
▲ 32% vs 2024
€ 74,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 1,261
▲ 29% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 176,435
▲ 100% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 287,473
▲ 56% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 1,470,216 | € 1,789,381 | € 1,906,025 | € 2,399,703 | ▲ 26% |
| Profit after taxes | € 939,127 | € 1,139,635 | € 984,888 | € 909,969 | ▼ 8% |
| Equity | € 69,300 | € 69,300 | € 69,300 | € 69,300 | |
| Total debts | € 1,125,460 | € 1,416,274 | € 1,265,139 | € 1,409,496 | ▲ 11% |
| Cash | € 484,462 | € 101,402 | € 130,701 | € 333,982 | ▲ 156% |
| Retained profit | € 6,300 | € 6,300 | € 6,300 | € 6,300 | |
| Dividend | € 939,127 | € 1,139,635 | € 984,888 | € 909,969 | ▼ 8% |
| Balance sheet total | € 1,194,760 | € 1,485,574 | € 1,334,439 | € 1,478,796 | ▲ 11% |
| Employees (FTE) | 8.9 | 8.6 | 11.3 | 15.1 | ▲ 3.8 |
Key figures of IN2PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to IN2PHARMA?
What happened at IN2PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 909,969 (▼ 8% vs 2024). Source: NBB ↗
- Ter Loonst BV became a director. NBB
- New establishment in Gent. KBO
- Patrick Van Dooren became a director. NBB
- Jeremy Dielen became a director. NBB
- Emmanuel Vanderhaegen became a director. NBB
- New establishment in Kampenhout. KBO
- Start of the company according to the CBE. KBO
In short
From € 939,127 profit in 2022 to € 909,969 profit in 2025.
Paid € 325,496 in corporate taxes since 2022.
Best year ever: 2023, with € 1.1 million profit.
On average € 158,900 of value added per employee in 2025.
A new publication or filing at IN2PHARMA? We notify you, reason included.
Follow IN2PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of PHC Group, C&N HOLDING comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
IN2PHARMABehind IN2PHARMA are Patrick Van Dooren, Ter Loonst BV, Jeremy Dielen and Emmanuel Vanderhaegen. The shares are held by PHC Group (100%) and C&N HOLDING (66.7%).
Directors
According to the 2025 annual accounts
since 2026
Persoon belast met dagelijks bestuur · represented by Caroline Steensels
Also active at: Arphius, C&N HOLDING, KDT Consulting, STUDIO PHARMA
since 2026
since 2026
since 2026
Shareholders
100%
66.7%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Terloonststraat 22
1910 Kampenhout
Kerkstraat 108
9050 Gent
Active since 2 April 2026
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 5 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Barracuda
Hosting
CLDIN-NL Your Hosting B.V. part of Your.Online, NL
Domain
Domain
in2pharma.com
Registered
2006-09-08
Registrar
Combell NV
Expires
2027-09-08
Website info
Features
Security
Details
- Company number
- 0895.730.662
- VAT number
- BE 0895.730.662
- Registered office
- Terloonststraat 22, 1910 Kampenhout
- Names & denominations
- IN2PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 29 January 2008
- Peppol
- Active · Active since 1 Jan 2001
- Contact
- in2pharma.com
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Overige gespecialiseerde wetenschappelijke en technische activiteiten